Benzinga | Jan 10, 2022 07:29AM EST

Agios Pharma Lists 2022 Milestones

-- Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February --



-- Five Pivotal Clinical Trials are Planned and Ongoing in Thalassemia, Sickle Cell Disease and Pediatric PK Deficiency --

-- Agios is Expanding Clinical Portfolio with Trials of Novel PK Activator AG-946 --

-- Strong Cash Position Expected to Enable Execution of Robust Operating Plan to Cash-Flow Positivity --